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COST-EFFECTIVENESS OF PREGABALIN AND OTHER ADD-
ON ANTIEPILEPTIC DRUG THERAPIES IN PATIENTS WITH
REFRACTORY PARTIAL EPILEPSY IN ARGENTINA
Aiello EC1,Thomson A2,Vera-Llonch M3, Elorza P1, Sadosky A4,
Oster G3
1Pﬁzer Argentina, Buenos Aires, Argentina, 2Hospital Francés, Buenos
Aires, Argentina, 3PAI, Brookline, MA, USA, 4Pﬁzer, Inc, New York, NY,
USA
OBJECTIVES: To estimate the cost-effectiveness of pregabalin
and other add-on antiepileptic drug therapies in patients with
refractory partial epilepsy [RPE] in Argentina METHODS:
Using simulation modeling techniques, we estimated clinical out-
comes and costs for a hypothetical cohort of 1000 patients with
RPE alternatively assumed to receive pregabalin (300 and 
600 mg/d), lamotrigine (300 and 500 mg/d), oxcarbazepine
(1200 and 2400 mg/d), topiramate (200 and 400 mg/d), and no
add-on therapy. Outcomes of interest were examined assuming
no therapy discontinuation and included the expected mean
number of days free of seizures (“seizure-free days” [SFD]) and
the costs of add-on antiepileptic medication over one year for
each therapy. Parameter estimates were based on efﬁcacy data
from randomized controlled trials of these agents and costs of
medications (in Argentine Pesos [ARS]) from local sources. Cost-
effectiveness was calculated as the incremental cost (vs no add-
on therapy) per additional SFD. RESULTS: The incremental cost
of pregabalin (vs no add-on therapy) per additional SFD was
(mean (95% CI), ARS) 117 (91,152) for pregabalin 300 mg/d,
194 (166, 228) for lamotrigine (300 mg/d), 120 (100,150) for
oxcarbazepine (2400 mg/d), and 235 (99, 1071) for topiramate
(400 mg/d). When higher dosages were examined values were
157 (132, 181) for pregabalin 600 mg/d, 306 (271, 356) for lam-
otrigine (500 mg/d), 176 (145, 212) for oxcarbazepine (2400
mg/d), and 196 (142, 269) for topiramate (400 mg/d). CON-
CLUSION: The estimated cost-effectiveness of add-on antie-
pileptic therapy vs no add-on therapy for patients with RPE in
Argentina is favorable for pregabalin (117–157 ARS per addi-
tional SFD) followed by OXC (120–176 ARS per additional
SFD).
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THE COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS
WITH RELAPSING MULTIPLE SCLEROSIS
Meyer K, Chiao E
Xcenda, Princeton, NJ, USA
OBJECTIVES: Natalizumab is a new disease-modifying therapy
(DMT) for the treatment of relapsing multiple sclerosis (MS). A
model was designed to determine the relative cost-effectiveness
of natalizumab compared with the other four currently available
disease-modifying therapies (intramuscular [IM] interferon beta
[IFNβ]-1a, IFNβ-1b, glatiramer acetate [GA], and subcutaneous
[SC] IFNβ-1a) for the treatment of relapsing MS in the United
States. METHODS: Analyses were conducted from a managed
care perspective with a time horizon of 2 years (ﬁrst 2 years after
initiation of therapy). Model inputs were drug acquisition costs,
costs of drug administration and monitoring, costs of treating
relapses, and anticipated reduction in relapse rates. Outcomes
included total 2-year costs per patient and costs per relapse
avoided for each therapy. Number of relapses avoided was cal-
culated as the weighted average number of relapses for placebo-
treated patients (1.90) multiplied by the anticipated relapse rate
reduction for each therapy (natalizumab, 67%; IM IFNβ-1a,
32%; IFNβ-1b, 34%; GA, 29%; and SC IFNβ-1a, 32%). Cost
per relapse avoided was calculated as the total 2-year cost of
therapy divided by the number of relapses avoided over 2 years.
RESULTS: The overall 2-year cost of therapy per patient was
$67,037 for natalizumab, $42,311 for IM IFNβ-1a, $44,680 for
IFNβ-1b, $44,300 for GA, and $46,373 for SC IFNβ-1a. The cost
per relapse avoided was lowest for natalizumab at $52,605 
followed by $69,091 for IFNβ-1b, $69,517 for IM IFNβ-1a,
$76,191 for SC IFNβ-1a, and $80,314 for GA. Model inputs with
the most inﬂuence on cost per relapse avoided for natalizumab
were weighted average number of relapses prior to treatment and
anticipated relative reduction in relapse rate. CONCLUSION:
Although the drug acquisition cost of natalizumab was higher
than that of the other DMTs, it was the most cost-effective therapy
as measured by total cost per relapse avoided.
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AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY BURDEN
OF INSOMNIA AND ITS TREATMENT
Hawkins K1,Treglia M2,Wang S3, Healey P4, Mendelson W5,
Harnett J4
1IMS Health, Brooklyn, MI, USA, 2Pﬁzer Inc, Groton, CT, USA,
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OBJECTIVES: The objective of this study was to estimate the
direct and indirect costs of treated and untreated insomnia in an
employed population. METHODS: The Medstat MarketScan®
Database was used for this study. Patients were included if they
had a primary diagnosis of insomnia and/or received a new pre-
scription for a non-benzodiazepine hypnotic medication between
July 1, 1999 and June 31, 2003. Total health care costs, plus
costs due to absenteeism, were calculated for the insomnia
cohort (n = 5605), and for the propensity score matched non-
insomnia cohort (total n = 55,580), during 6-month pre-index
and post-index periods. Change in total costs were compared
using an ordinary least square model for insomnia patients who
were treated versus not initially treated with a prescription hyp-
notic within 14 days of an insomnia diagnosis. RESULTS: Prior
to matching, the insomnia cohort was slightly younger (40 vs.
42 years), more likely to be female (44% vs 31%), and had sig-
niﬁcantly more medical and psychiatric comorbidity than the
non-insomnia cohort (Charlson Comorbidity Index score 0.32
vs. 0.11; P < 0.01). After using propensity score matching and
second stage regressions, the difference in average total expen-
ditures in the 6-month post-index period between the cohort of
insomnia patients (n = 5584) and matched non-insomnia con-
trols—the burden of insomnia—was $2738 (p < 0.001). Health
care utilization contributed to 84% of total insomnia-related
costs, while absenteeism contributed 16%. Six-month costs for
prescription hypnotics averaged less than $100 per patient. Both
the treated and initially untreated insomnia patients experienced
an increase in total costs; however, the increase for treated
insomnia patients was $788 less than for the initially untreated
insomnia patients. CONCLUSION: Insomnia has a signiﬁcant
impact on direct health care cost, and on costs related to absen-
teeism. Insomnia treatment appears to be cost-effective relative
to non-treatment, or delayed treatment.
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LIFETIME CLINICAL AND ECONOMIC CONSEQUENCES OF
CHANGES IN BODY WEIGHT ASSOCIATED WITH MIGRAINE
HEADACHE PROPHYLAXIS WITH TOPIRAMATE VERSUS
AMITRIPTYLINE
Vera-Llonch M1, Rupnow MF2, Gagne JJ2, Siu T1, Oster G1
1PAI, Brookline, MA, USA, 2Ortho-McNeil Janssen Scientiﬁc Affairs,
LLC,Titusville, NJ, USA
OBJECTIVES: To estimate expected clinical and economic 
consequences of induced changes in body weight associated 
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with migraine headache prophylaxis with topiramate versus
amitriptyline. METHODS: Lifetime incidence and costs of car-
diovascular disease (CVD) were estimated for patients receiving
topiramate or amitriptyline as migraine headache prophylaxis.
Projections were based on a model of the clinical and economic
consequences of overweight and obesity, and data from a recent
six-month controlled clinical trial of these agents, which demon-
strated that they were equally effective in preventing migraines.
Analyses were undertaken for a hypothetical cohort of 1000
women, aged 35 to 44 years at therapy initiation, with pre-treat-
ment body mass index (BMI) of 28. Topiramate patients were
assumed to experience a 1.26 unit decrease in BMI at six months,
based on clinical trial data; and amitriptyline patients were
assumed to experience an increase of 1.51; changes were
assumed to persist over a lifetime. Model outcomes included
expected lifetime cumulative incidence of coronary heart disease
(CHD) and stroke, and life expectancy. Expected lifetime costs
were calculated based on estimated event risk and associated
medical-care costs, using a third-party payer perspective. Costs
were discounted at 3% annually. RESULTS: As a result of
changes in BMI, the estimated prevalence of hypertension, hyper-
cholesterolemia, and diabetes was higher for amitriptyline versus
topiramate at all future ages. Amitriptyline patients were 
also estimated to develop an additional 18 cases of CHD (per
1000 patients) compared to those receiving topiramate. Life
expectancy was 0.4 years longer for topiramate patients, and
their lifetime cumulative direct costs of CVD and metabolic
disease were about $3500 lower than those for amitriptyline.
CONCLUSION: Migraine headache prophylaxis with topira-
mate rather than amitriptyline may yield important clinical and
economic beneﬁts as a result of differences in induced changes
in body weight.
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IMPACT OF RELAPSES ON TOTAL COSTS OF CARE FOR
PATIENTS WITH MULTIPLE SCLEROSIS
Bennett R1, Cisternas M2, Foreman AJ2, Miller DP2,AL-Sabbagh A3
1Serono, Inc, Rockland, MA, USA, 2Ovation Research Group, San
Francisco, CA, USA, 3Serono, Rockland, MA, USA
OBJECTIVES: We investigate the impact of recurrent relapses
on short- and long-term health care costs in the United States.
Relapses in multiple sclerosis (MS) are a major burden on
patients’ welfare and related health care costs, and have been
shown to impact residual disability. While relapse costs have
been reported previously, no publication has examined the
impact of recurrent relapses on total health care costs.
METHODS: We used medical (International Classiﬁcation of
Diseases-9 diagnoses) and pharmacy claims from a large, US
National Health Plan database to identify MS patients with >=1
relapse who had enrolled in the plan between 2002–2004, and
who had continuous enrolment 6 months pre- and 12 months
post-index relapse. Costs were estimated based on claim charges,
and were adjusted to project the amount in 2005 US dollars.
Analyses were stratiﬁed by newly or previously diagnosed
patients, and the number of relapses. Costs are presented in 90-
day intervals in reference to the index relapse period (days 0–30).
RESULTS: Newly diagnosed patients with >=2 relapses had
higher monthly costs compared with patients with 1 relapse only
at days 0–30 (index relapse) ($26,890 vs. $16,121), 31–90
($3597 vs. $1506), and 271–360 ($3768 vs. $1074). Although
previously diagnosed patients with >=2 relapses had costs similar
to those of patients with 1 relapse only at index relapse at days
0–30 ($21,350 vs. $21,015), monthly costs were higher for
patients with >=2 relapses at days 31–90 ($3792 vs. $2712) and
remained higher at days 271–360 ($3636 vs. $1676). Monthly
costs were generally higher for previously diagnosed patients
with the exception of the acute phase of relapse (days 0–30) in
the >=2 relapses subset. CONCLUSION: Recurrent relapses are
associated with increased costs, both in the acute phase of man-
aging a relapse and during the follow-up year in both newly diag-
nosed and previously diagnosed patients.
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HEALTH CARE COSTS AND UTILIZATION FOR ALZHEIMER’S
DISEASE PATIENTS
Zhao Y1, Kuo TC2,Weir S3, Kramer MS2,Ash AS4
1Eli Lilly and Company, Indianapolis, IN, USA, 2DxCG, Inc, Boston, MA,
USA, 3University of Massachusetts Medical School, Shrewsbury, MA,
USA, 4Boston University, Bosotn, MA, USA
OBJECTIVES: To examine comorbidity associated with
Alzheimer’s disease (AD) and cost drivers using administrative
claims. METHODS: We studied over-age-65 individuals with
pharmacy beneﬁts with employer-sponsored Medicare supple-
mental insurance in 2003–2004. AD patients were identiﬁed by
having ≥1 claim with an AD diagnosis or ≥1 ﬁlled prescription
for medication used exclusively for AD treatment in 2003. We
used propensity scoring to select demographically-matched, 
non-demented Controls (3 : 1 ratio to AD) and compared these
groups for disease prevalence (via a comprehensive classiﬁcation
system, Diagnostic Cost Groups (DCGs)), 2004 cost distribu-
tions, and reasons for ER visits and inpatient admissions. We
used logistic regression to assess the marginal contribution of AD
to the most common reasons for ER and inpatient admissions,
using DCGs to control for total illness burden. RESULTS: Com-
pared with controls (n = 75,327), AD patients (n = 25,109) have
more comorbid medical conditions (8.1 vs. 6.5) and higher
($13,936 vs. $10,369) but less variable (CVs = 181 vs. 324)
costs. Both groups expend one-third of overall costs on inpatient
services, ≤29% on prescriptions, and ≥38% on outpatient ser-
vices. Not only do more AD patients use ERs (27% vs. 42%)
and hospitals (30% vs. 20%), but their hospitalizations are
longer (3.38 vs. 1.93 days). Chest pain and contusion/superﬁcial
injury are the top two reasons for ER visits for both groups.
Three of the top 4 reasons for inpatient admissions are also the
same: pneumonia, hip fracture and heart failure. However, even
after controlling for their excess illness burden, AD patients are
at higher risk for hospitalizations due to hip fracture and pneu-
monia (odds ratios = 2.29 and 1.48, respectively). CONCLU-
SION: AD patients have signiﬁcantly more comorbid disease,
and are more likely to incur ER visits and inpatient admissions,
than age-and-sex matched controls, even after adjusting for
comorbidity differences.
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ECONOMIC CONSEQUENCES OF THERAPEUTIC
ALTERATION IN THE MANAGEMENT OF INSOMNIA
Pollack M1, Joish V2, Cziraky MJ1
1HealthCore, Inc, Wilmington, DE, USA, 2Sanoﬁ-Aventis, Bridgewater,
NJ, USA
OBJECTIVES: Pharmaceutical options for insomnia that treat
both sleep induction and maintenance have only recently been
launched in the U.S. The economic impact of treatment patterns
with older drugs has not been thoroughly investigated in the lit-
erature. We hypothesized that since the older drugs only pro-
vided beneﬁt for sleep induction, insomniacs who alternate
therapy within one year of initiation would have greater eco-
nomic burden compared to maintainers. METHODS: Treated
insomnia patients were identiﬁed from Medstat Marketscan
claims database with at least one prescription for existing insom-
nia agents during the study period (05/01/01 to 11/30/03).
